摘 要：散發(fā)性腎透明細(xì)胞癌中存在凡黑普爾-林道基因的突變，腎癌細(xì)胞的生長主要依賴血管內(nèi)皮生長因子（VEGF），因此，以VEGF為靶點的藥物廣泛應(yīng)用于腎癌的臨床治療。重組性單克隆抗體（如貝伐單抗）和與VEGF受體相結(jié)合的小分子抑制劑（如舒尼替尼、索拉非尼、阿西替尼、帕唑帕尼、瓦他拉尼）臨床療效已得到了驗證，表現(xiàn)出較高的應(yīng)答率、無進(jìn)展生存時間的延長并提高了腎癌患者總生存率。就VEGF抑制劑的作用靶點、機(jī)制、治療后患者敏感性以及臨床試驗等做一簡要綜述，為抗腫瘤藥物研發(fā)提供思路。

Abstract：Von hippel-lindau gene mutation is very common in sporadic renal cell carcinoma，and vascular endothelial growth factor（VEGF）plays an important role in the growth of cancer cells．Therefore，VEGF-targeted drugs have been widely used in clinic treatment of renal cell carcinoma．Many VEGF-targeted drugs have been proved good therapeutic effects，including recombinant monoclonal antibodies（such as Bevacizumab）and small-molecule inhibitors that bind with VEGF receptors（such as Sunitinib，Sorafenib，Axitinib，Pazopanib，and Vatalanib）．Those medicines prolong the progression-free survival（PFS）and increase total survival rate of patients with renal cell carcinoma．This paper reviews the target site，function mechanism，patient sensitivity and clinic test of VEGF-targeted drugs，so as to provide certain help for the research and development of anti-tumor drugs．